FR3052779B1 - Nouvelles proteines de fusion et leur application pour la preparation de vaccins - Google Patents

Nouvelles proteines de fusion et leur application pour la preparation de vaccins Download PDF

Info

Publication number
FR3052779B1
FR3052779B1 FR1655677A FR1655677A FR3052779B1 FR 3052779 B1 FR3052779 B1 FR 3052779B1 FR 1655677 A FR1655677 A FR 1655677A FR 1655677 A FR1655677 A FR 1655677A FR 3052779 B1 FR3052779 B1 FR 3052779B1
Authority
FR
France
Prior art keywords
vaccines
preparation
application
fusion proteins
novel fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1655677A
Other languages
English (en)
Other versions
FR3052779A1 (fr
Inventor
Christophe Hourioux
Romuald Patient
Elodie BEAUMONT
Philippe Roingeard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Regional Universitaire de Tours
Universite de Tours
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Francois Rabelais de Tours
Centre Hospitalier Regional Universitaire de Tours
Universite de Tours
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM, Universite Francois Rabelais de Tours, Centre Hospitalier Regional Universitaire de Tours, Universite de Tours filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Priority to FR1655677A priority Critical patent/FR3052779B1/fr
Priority to US16/310,666 priority patent/US10766930B2/en
Priority to EP17740437.3A priority patent/EP3472182A1/fr
Priority to CN201780038144.8A priority patent/CN109715649A/zh
Priority to PCT/FR2017/051591 priority patent/WO2017216505A1/fr
Priority to ARP170101706A priority patent/AR108844A1/es
Publication of FR3052779A1 publication Critical patent/FR3052779A1/fr
Application granted granted Critical
Publication of FR3052779B1 publication Critical patent/FR3052779B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR1655677A 2016-06-17 2016-06-17 Nouvelles proteines de fusion et leur application pour la preparation de vaccins Expired - Fee Related FR3052779B1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR1655677A FR3052779B1 (fr) 2016-06-17 2016-06-17 Nouvelles proteines de fusion et leur application pour la preparation de vaccins
US16/310,666 US10766930B2 (en) 2016-06-17 2017-06-16 Fusion proteins and use thereof for preparing vaccines
EP17740437.3A EP3472182A1 (fr) 2016-06-17 2017-06-16 Nouvelles proteines de fusion et leur application pour la preparation de vaccins
CN201780038144.8A CN109715649A (zh) 2016-06-17 2017-06-16 新型融合蛋白和其用于制备疫苗的用途
PCT/FR2017/051591 WO2017216505A1 (fr) 2016-06-17 2017-06-16 Nouvelles proteines de fusion et leur application pour la preparation de vaccins
ARP170101706A AR108844A1 (es) 2016-06-17 2017-06-21 Proteínas de fusión y su aplicación en la preparación de vacunas

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1655677 2016-06-17
FR1655677A FR3052779B1 (fr) 2016-06-17 2016-06-17 Nouvelles proteines de fusion et leur application pour la preparation de vaccins

Publications (2)

Publication Number Publication Date
FR3052779A1 FR3052779A1 (fr) 2017-12-22
FR3052779B1 true FR3052779B1 (fr) 2018-06-22

Family

ID=57233563

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1655677A Expired - Fee Related FR3052779B1 (fr) 2016-06-17 2016-06-17 Nouvelles proteines de fusion et leur application pour la preparation de vaccins

Country Status (6)

Country Link
US (1) US10766930B2 (fr)
EP (1) EP3472182A1 (fr)
CN (1) CN109715649A (fr)
AR (1) AR108844A1 (fr)
FR (1) FR3052779B1 (fr)
WO (1) WO2017216505A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021232165A1 (fr) * 2020-05-22 2021-11-25 University Of Saskatchewan Virus oncolytiques recodés pour le traitement du cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2932388B1 (fr) * 2008-06-17 2013-03-29 Univ Rabelais Francois Nouvelles proteines de fusion et leur application pour la preparation de vaccins contre l'hepatite c
CN105821078A (zh) * 2010-12-09 2016-08-03 巴斯德研究所 用于获得高产量重组蛋白表达的基于mgmt的方法

Also Published As

Publication number Publication date
FR3052779A1 (fr) 2017-12-22
US10766930B2 (en) 2020-09-08
US20190389912A1 (en) 2019-12-26
CN109715649A (zh) 2019-05-03
AR108844A1 (es) 2018-10-03
EP3472182A1 (fr) 2019-04-24
WO2017216505A1 (fr) 2017-12-21

Similar Documents

Publication Publication Date Title
ZA201808284B (en) Gdf15 fusion proteins and uses thereof
HK1246317A1 (zh) 免疫調節融合蛋白及其用途
HK1257056A1 (zh) 抗dll3抗體藥物綴合物以及使用方法
IL265657A (en) Immunomodulatory fusion proteins
EP3155018A4 (fr) Protéines de fusion à anticorps à région constante et compositions les contenant
CL2018000813A1 (es) Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso.
MA46466A (fr) Formulations pharmaceutiques de protéines à viscosité réduite
MA49726A (fr) Formulation d'anticorps anti-cgrp
DK3368554T3 (da) Langtidsvirkende fgf21-fusionsproteiner og farmaceutisk sammensætning omfattende samme
MA55347A (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
EP3142645A4 (fr) Compositions pharmaceutiques et procédés de fabrication de masses solides comprenant des polypeptides et/ou des protéines
SG11201705585QA (en) Anti-myostatin antibodies and methods of use
IL281426A (en) New conjugates of montelukast and peptides
MA50908A (fr) Formulations de protéines de fusion vegfr-fc
IL262752B (en) Construction of transgenic bacteria for high expression of recombinant albumin from human serum
MA43717A (fr) Anticorps anti-tnf et fragments fonctionnels de ceux-ci
DK3199179T3 (da) Formulering af rekombinant fusionsprotein
HK1250662A1 (zh) 用於治療癌症的免疫原性融合蛋白
IL266132B (en) Pharmaceutical formulations and methods for their preparation
PL3639845T3 (pl) Kompozycja farmaceutyczna zawierająca kompleks białka il-15 i jej zastosowania
DK3608334T3 (da) Tatk-cdkl5-fusionsproteiner, sammensætninger, formuleringer og anvendelse deraf
EP3419651C0 (fr) Formulation de la protéine de fusion naglu améliorée
MA43715A (fr) Anticorps anti-tnf et fragments fonctionnels correspondants
KR20180084995A (ko) Fmdv 및 e2 융합 단백질 및 이의 용도
MA43716A (fr) Anticorps anti-tnf et fragments fonctionnels de ceux-ci

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20171222

PLFP Fee payment

Year of fee payment: 3

TQ Partial transmission of property

Owner name: CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE T, FR

Effective date: 20180517

Owner name: UNIVERSITE FRANCOIS RABELAIS DE TOURS, FR

Effective date: 20180517

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20180517

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

ST Notification of lapse

Effective date: 20230205